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Recent changes on the biopharmaceutical 
market after the introduction  
of biosimilar G-CSF products
ABSTRACT
The biologic medicine market is the fastest growing segment of the global pharmaceutical market. However, the 
high price of biologic medicines is a challenge for the constrained budget of healthcare systems. The introduction 
of biosimilars — copies of therapeutic biologics — has ensured a high degree of competition on the market and 
consequently has expanded patient access to advanced therapies and has evolved the overall patient treatment 
costs. One of the first medicines that was approved in Europe based on the abbreviated registration process 
was a biosimilar version of filgrastim. In this review we investigate the impact of biosimilar G-CSF products on 
the market. The influence of the competition on the price change and the cost of therapy were analysed. Our 
findings reveal that the impact of biosimilars on the healthcare system is multi-factored and therefore difficult to 
predict. A competitive environment induces the price reduction even for second-generation products. However, 
at the same time, no correlation between the biosimilar market share and the discount was noticed. It seems 
that the observed changes reflect the mix of economic conditions including the situation on the national market 
before introduction of biosimilars, local adoption of treatment practices influenced by the pricing system, and the 
payer’s decision on drug reimbursement.
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Introduction
Annual global spending on biologic medicines 
is expected to account for more than $200 billion in 
2016 [1]. This segment of the pharmaceutical market is 
continuously growing as many companies perceive their 
future in biologics. In 2014, five from ten top-selling 
pharmaceuticals were biologics [2]. The high price of 
biologic medicines is a challenge for the constrained 
budget of healthcare systems, though. The average 
daily cost of a biologic is about 20 times higher than 
a small-molecule drug [3]. The introduction of biosimi-
lars has ensured a high degree of competition on the 
market and consequently has expanded patient access to 
advanced therapies and has evolved the overall patient 
treatment costs. 
One of the first medicines that gained EMA ap-
proval based on the abbreviated registration process 
was a biosimilar version of filgrastim. Filgrastim is 
a recombinant granulocyte colony-stimulating factor 
(G-CSF) that stimulates the bone marrow to produce 
granulocytes and stem cells and release them into the 
bloodstream [4]. The drug is widely used to treat severe 
chronic neutropaenia (SCN), to prevent and accelerate 
the recovery from neutropaenia in patients with HIV or 
after chemotherapy, and to mobilise peripheral blood 
progenitor cells (PBPC).
For many years, the competition on the G-CSF 
market was very limited. Only two products, Neupogen® 
(INN filgrastim) and Neulasta® (INN PEG-filgrastim) 
— the long-acting analog, launched by one company 
— Amgen, captured almost the entire global market. 
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The main competitor, lenograstim (recombinant G-CSF 
produced in mammalian cells), did not play the signifi-
cant role, reaching 5% of the market share in 2007 [5]. 
The situation changed noticeably in 2008, when bio-
similar versions of filgrastim were launched in Europe, 
capturing about 80% of the market in 2014. The average 
price of the drug declined, in both the biosimilar/ref-
erence group (–19%) and in the whole product class 
(–28%), including the long-acting filgrastim analogs and 
lenograstim. Simultaneously, a drug uptake increase of 
about 100% was noticed [6]. However, these changes 
varied across European countries indicating that crucial 
factors driving biosimilar market performance played 
out differently across the national markets. 
The purpose of this review was to assess the im-
pact of the biosimilar G-CSF products on the market. 
Furthermore, the influence of the competition on the 
price changes and cost of the therapy was investigat-
ed. Parameters such as a change in average price, the 
biosimilar market share, and the uptake development 
were analysed. Our findings reveal that the impact of 
biosimilars on patient care and the healthcare system is 
multi-factored and therefore difficult to predict. A com-
petitive environment induced price reduction even for 
the second-generation products. At the same time, no 
correlation between the biosimilar market share and the 
discount was noticed. It seems that the observed changes 
reflect the mix of economic conditions, including the 
situation on the national market before the introduction 
of biosimilars, local adoption of treatment practices in-
fluenced by the pricing system, and the payer’s decision 
on drug reimbursement. 
G-CSF market before introduction  
of biosimilars 
In the early 1990s two recombinant G-CSF products 
appeared on the biopharmaceutical market. The first 
one, Neupogen® (INN: filgrastim), was launched by 
Amgen on the American and European market [7]. The 
second one, INN: lenograstim, appeared on the Asian 
market branded as Neutrogin® (Chagai Pharmaceuti-
cals) and three years later on the European market as 
Granocyte (Chugai-Rhone-Poulenc) [8, 9]. Even though 
the structures of both products differ as a consequence 
of the production processes, lenograstim and filgrastim 
have been characterised as having the same mechanism 
of action and similar clinical characteristics [10].
Unlike filgrastim, which is manufactured in E. coli 
and is not glycosylated, lenograstim is produced in mam-
malian cells (CHO) and exhibits a glycosylation pattern 
similar to that in native G-CSF [11]. Is this difference 
crucial for the drug’s efficiency and safety? Several in 
vitro studies have shown that filgrastim has a lower 
affinity to the cell receptor G-CSFR than lenograstim 
and can alter the signal path, which leads to increased 
production of leucocytes with a disrupted morphology 
and mobility [11–14]. On the other hand, cumulative 
data from patients and healthy volunteers received in 
comparative clinical trials did not reveal significant 
differences in terms of such clinical parameters as the 
number of CD34+ cells, and demonstrated no clear 
reasons to prefer lenograstim over filgrastim in their 
approved indications [15–19]. 
The competitive G-CSF products appeared on the 
market at a similar time and were believed to be equally 
safe and effective. However, it was filgrastim that dom-
inated the market. The global sale of Neupogen® was 
growing continuously and reached 1.3 billion dollars in 
1999 [20]. There were several reasons for that. First of 
all, the marketing strategy. Filgrastim was distributed 
on the biggest world markets by two joint ventures: 
Krin-Amgen (America, Asia) and Amgen-La Roche 
(Europe). This business model allowed targeting of the 
marketing campaign precisely. Chugai Pharmaceutical, 
a producer of the competitive product, cooperated 
with numerous companies to distribute lenograstim 
in different regions. It could have distracted the mar-
keting actions and caused lower sales. Secondly, Am-
gen could compete on the price as the DNA-derived 
technology based on E. coli cells is much cheaper than 
the lenograstim production based on mammalian cells 
[21]. It is a likely reason why glycosylated G-CSF was 
more expensive than filgrastim [22]. Moreover, several 
pharmacoeconomic analyses have shown that the price 
might be a crucial parameter in evaluating the G-CSF 
treatment strategy [23, 24]. Thirdly, and probably most 
importantly, lenograstim was not introduced on the 
American market, which has the largest share of bio-
pharmaceutics sales [2]. 
The success of Neupogen and its domination on the 
market did not stop Amgen from further development. 
A long-acting filgrastim analog, PEG-filgrastim (Neulas-
ta®), was approved in 2002 by the FDA and in 2005 by 
the EMA. Numerous pharmacoeconomic evaluations 
showed that PEG-filgrastim was more cost-effective 
than the therapy based on filgrastim, even when very 
low prices of filgrastim and high prices of PEG-filgrastim 
were assumed [25–28]. Therefore, Neulasta® became 
a new sales leader. In 2007, its sales accounted for 51% 
of the G-CSF market worldwide, which was worth of 
5.6 billion dollars. The second position with a share of 
sales of 1.3 billion dollars (24%) was taken by Neupo-
gen®. About 18% of the market belonged to products 
with filgrastim marketed under other brand names. At 
the same time, lenograstim sales accounted for only 
about 5% of the G-CSF market [5]. 
146
OncOlOgy in clinical practice 2016, Vol. 12, No. 4
Biosimilar filgrastim — regulatory 
aspects and development costs
From 2008 to 2015 the EMA approved eight bio-
similar G-CSF products (INN: filgrastim) based on four 
independent dossiers (Table 1). For all of them Neupo-
gen® was the reference product. To date, no biosimilar 
lenograstim has been introduced. In the US, the first 
competitor for Neupogen® appeared in 2012 when Teva 
gained FDA approval for Granix® (INN: tbo-filgrastim) 
according to the procedure for new biologics [29]. The 
first biosimilar G-CSF product, Zarxio® (INN: filgras-
tim-sndz), was approved by the FDA in 2015. The drug 
was introduced on the American market by Sandoz, one 
of the leading generic companies [30]. 
The main cost burden of biologics development rests 
on the clinical studies — the most expensive and risky 
stage. The EMA guidelines on similar medicinal prod-
ucts containing recombinant granulocyte-colony stimu-
lating factor (CHMP/31329/05) provide two models for 
conducting clinical trials. The first one assumes the per-
formance of comparative phases I and III studies. Phase 
I should test the pharmacokinetic and pharmacodynamic 
parameters of the biosimilar and a reference product in 
a single dose crossover study. The aim of phase III is to 
prove the safety of the drug and demonstrate its clinical 
comparability in a chemotherapy-induced neutropaenia 
study. The alternative model is possible under certain 
conditions and after consulting with EMA experts. It 
involves the extension of phase I to demonstrate the 
clinical comparability and reduction of the phase III 
role, which is treated as supportive. Questions remain 
if this approach is in accordance with the philosophy of 
biosimilar guidelines in the safety aspects and why the 
CHMP treats sponsors in an unequal way. 
Two submissions of the biosimilar filgrastim 
approved by the EMA were based on  comparative 
phase III studies: Teva/Ratiopahrm’s filgrastim and 
Pliva/Hospira’s filgrastim. Teva/Ratiopharm performed 
the widest set of exercises, which significantly exceeded 
the requirements, even in non-clinical aspects. In total, 
the sponsor conducted two comparative phase I studies 
that involved 200 healthy volunteers, and three compar-
ative phase III studies encompassing 350 breast cancer 
patients, 240 lung cancer patients, and 92 non-Hodgkin 
lymphoma patients [31]. The reason for such extended 
studies was the sponsor’s business strategy. The same 
data was later used by Teva to support the FDA submis-
sion for tbo-filgrastim [32]. Pliva/Hospiria’s filgrastim 
submission was supported by two comparative phase I 
studies that comprised 100 healthy volunteers, and one 
comparative phase III study involving 279 breast cancer 
patients [33]. Sandoz and Intas Biotech./Apotex were 
allowed to design an alternative model of clinical trial. 
Both sponsors conducted four comparative phase I stud-
ies that encompassed, respectively, 146 and 235 healthy 
volunteers, and one non-comparative phase III study 
that involved, respectively, 170 and 120 breast cancer 
patients [34, 35]. At this point, it is obvious that the 
expenses for developing the biosimilar filgrastims varied 
considerably. The average cost per patient is highest for 
phase III [36, 37], and this allows us to assume that the 
alternative models of clinical trials were more cost-ef-
fective for the sponsors. 
Submission of the first and at this moment the only 
biosimilar filgrastim approved by the FDA, Zarxio® 
(filgrastim-sndz), was partially based on the same exer-
cises that had supported the product of Sandoz in the 
European approval procedure. Analytical bridging tests 
comparing Zarxio®, UE-approved Neupogen®, and the 
US-licensed Neupogen® provided relevant informa-
tion for acceptation of preclinical and clinical studies 
conducted with the UE-marketed reference product. 
However, Sandoz had to perform an additional, com-
parative phase III study with 218 breast cancer patients 
to prove biosimilarity in the efficiency and safety aspects 
between Zarxio® and the US-licensed Neupogen® [38]. 
Filgrastim-sndz received the license for all indications 
Table 1. A list of biosimilar G-CSF products with EMA approval
Brand name Developed by Marketing Authorisation Holder Authorisation 
data
Tevagrastim®
BioGeneriX (Ratiopharm GmbH) and 












Nivestim® Pliva Croatia and Hospira Zagreb d.o.o. Hospira UK Ltd. 8.06.2010
Grastofil® Intas Biopharmaceuticals Ltd. and
Apotex Nederland B.V.
Apotex Europe B.V. 18.10.2013
Accofil® Accord Healthcare Ltd 18.10.2014
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for which Neupogen® was approved in the US. In con-
trast, tbo-filgrastim, submission of which was supported 
by a wider set of preclinical and clinical studies, was 
approved for only one indication: to reduce  chemother-
apy-induced neutropaenia in patients with non-myeloid 
malignancies. Sandoz’s development strategy seems to be 
the most cost-effective. It clearly shows that the develop-
ment costs of biologics can be significantly limited in the 
procedure for biosimilars. However, some doubts remain 
in the safety aspects. In 1998, Neupogen® gained FDA 
approval for an additional indication (not approved in 
the EU): to reduce chemotherapy-induced neutropenia 
in patients with acute myeloid leukaemia (AML). Amgen 
had to prove the safety and efficiency of the product for 
this indication in a large phase III study with 400 enrolled 
patients [39]. In 2015, this indication was automatically 
extrapolated to Zarxio® without any additional study on 
patients with AML. 
Competition for long-acting filgrastim 
(PEG-filgrastim)
The changes on the G-CSF market were not only 
involved with the introduction of biosimilar versions of 
filgrastim. In 2013, Teva launched in Europe a competitor 
for Neulasta®. Lipegfilgrastim, branded as Lonquex®, 
gained EMA approval as a new biologic medicine [40]. 
Both competing products were produced by conjugation 
of a single PEG group to filgrastim. However, the sites and 
the PEGylation processes were different. Consequently, 
the pharmacokinetic and pharmacodynamic profiles var-
ied. Despite that, the comparative clinical trials showed 
no significant difference in the efficiency and safety of 
both competitors [41]. These results entailed that Amgen 
was more willing to compete with the price in Europe. In 
the US the FDA approval for Lonquex® was successfully 
blocked. However, the US patent protection for long-acting 
PEG-filgrastim expired in October of 2015 and the position 
of Neulasta® on the American market has been threat-
ened because Amgen faces another rival. In December 
2014 Apotex was accepted by the FDA filing an application 
for the biosimilar version of PEG-filgrastim [42]. 
Price change of G-CSF products 
The price decrease was the most expected conse-
quence of the introduction of biosimilars on the market. 
The evaluation from 2014 showed that the price of fil-
grastim was very easily affected by the competition. In 
Europe, from 2007 to 2014, the average price [expressed 
as price per treatment day (TD)] of a biosimilar/ref-
erence product was reduced by 19%. However, most 
surprising was the 28% reduction of the average price 
in the whole product class. That includes long-acting 
filgrastim analogs and lenograstim. On the other hand, 
no correlation between the biosimilar market share 
(expressed as treatment day per defined daily dose) and 
the price reduction was observed [6]. The comparison 
of these two parameters for each European country is 
depicted in Figure 1. The highest price reduction (more 
Figure 1. The biosimilar market share (in 2014) and the price reduction (2014/2007) in European countries. Prepared based on [6]. 
TD — treatment day
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Figure 2. The uptake development in the biosimilar/reference group and in the whole product class (2014/year before biosimilar 
introduction) in European countries. Prepared based on [6]. TD — treatment day
than 40%) was observed in Portugal, Slovakia, Slovenia, 
Romania, Greece, and Poland. Moreover, for countries 
like Sweden, the UK, Norway, Italy, Hungary, Denmark, 
Germany, and Austria the discount in the whole product 
class was greater than for the biosimilar/reference group. 
The presented data clearly show that even the low share 
of biosimilars on the market had a significant impact on 
the price change, but the high share did not guarantee 
a large price decline. Such changes on the national 
markets were caused by the mix of several factors like 
the starting price, the refunding and pricing system of 
each country, and its economic condition.
The first competitor of Neupogen® in the United 
States, Granix®, was lunched on the market in Novem-
ber of 2013. In the following year, it captured approx-
imately 11% of short-acting G-CSF volume [43]. Teva 
offered its product with a 15% discount [44]. However, 
tbo-filgrastim, which has limited indication range, did 
not force Amgen into a price war. Perhaps a biosimilar, 
Zarixo®, which was launched in 2015, also with a 15% 
discount, will cause greader price evolution in the US. 
Evolution of uptake of G-CSF products 
The price reduction seemed to have a significant 
impact on the increased access to G-CSF products. How-
ever, the uptake development (expressed in treatment 
days) varied considerably across different European 
countries (Fig. 2). The most meaningful growth in the 
whole product class was observed in Romania (1621%), 
Slovakia (734%), Poland (474%), and Slovenia (272%). 
It can be assumed that the high price limited the uptake 
of G-CSF products in these countries. The competitive 
environment allowed fitting the price and effectively 
reducing the treatment costs. However, as presented 
in Figure 3, different uptake development in Romania, 
Slovakia, Poland, and Slovenia was caused by similar dis-
counts. It seemed that other factors, such as the starting 
uptake, local adoption of treatment practices, and payer 
actions, affected the uptake increase. Probably, one of 
the most influential factors was a cost-sharing system 
that defined an apparent patient fee. In each country 
the systems combined several cost-sharing models that 
divided the overall cost of the medicine between the 
payer and  the patient. For instance, Polish patients paid 
a lump sum fee or a percentage rate of the full price. In 
Slovenia, medicines were reimbursed by about  75% of 
the price by obligatory insurance and the rest was paid 
by voluntary insurance or by the patient. This could 
cause disproportion between the uptake development 
in Poland and Slovenia (Fig. 3).
The second interesting group of countries was Bel-
gium, Czech, Denmark, Ireland, and the Netherlands, 
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Figure 3. The price change and the uptake development 
in biosimilar/reference group and in the whole product 
class (2014/year before biosimilar introduction) in Poland, 
Slovakia, Slovenia, and Romania. Prepared based on [6]. TD 
— treatment day
Figure 4. The price change and the uptake development in 
biosimilar/reference group and in the whole product class 
(2014/year before biosimilar introduction) in Belgium, the 
Czech Rep., Denmark, Ireland, and the Netherlands. Prepared 
based on [6]. TD — treatment day
Figure 5. The price change and uptake development in the 
biosimilar/reference group and in the whole product class 
(2014/year before biosimilar introduction) in France, Hungary, 
Italy, and Sweden. Prepared based on [6]. TD — treatment day
for which the uptake in the whole product class rose 
significantly (50–200%), whereas a very low increase 
or even reduction of the uptake in the biosimilar/refer-
ence group was noticed (Fig. 4). These results indicate 
that under some circumstances competition in the 
biosimilar/reference group increases access to analog 
products. On the other hand, in France, Hungary, Italy, 
and Sweden the uptake development of biosimilar/refer-
ence products was significantly higher than in the whole 
product class (Fig. 5). These surprising findings are dif-
ficult to explain because the reimbursement systems of 
these countries are very different. However, they could 
indicate that another factor, for example the habits of 
a particular physician or the local treatment procedures, 
affected the oserved changes. 
In some countries such as Portugal, Greece, and 
Spain, which struggled with economic crisis, uptake 
reduction or stagnation in the whole product class was 
observed. Uptake growth in the biosimilar/reference 
group was noticed in Portugal (27%) and Spain (47%), 
although in Greece, the most touched by crisis, the 
uptake decreased by 48% [6]. 
Treatment cost savings
The range of indications for G-CSF products has 
expanded greatly in recent years, e.g. as a support for 
high-dose chemotherapy or haematopoietic stem cell 
collection, which is increasingly widely used for trans-
plant procedures especially in haematological malig-
nancies. The price reduction and the following uptake 
increase meant that the overall cost of G-CSF products 
in Europe was higher in 2013 compared to 2006 (Fig. 6). 
The highest growth of spending was noticed in Romania 
(600%) and Poland (213%), and the lowest in the Czech 
Republic (3%) and Sweden (6%) [45]. These observa-
tions are surprising, but in fact they reflect the difference 
in the refunding system of each country. Payer decisions 
are based on the evaluation of the therapeutic strategy, 
which usually includes the therapeutic efficiency and the 
financial aspects. High growth of spending in some coun-
tries indicates that the refunding decision was focused 
on the medicine unit costs rather than a broader view 
that considers the full cost of medicine administration 
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to patients. In the long perspective this approach could 
be risky. Especially when the prescription rules are 
insufficiently supervised by health authorities. On the 
one hand, the expanded range of indications for G-CSF 
products increases the patients access to the drug. 
However, on the other hand the high financial burden 
may overwhelm the payer budget and in turn lead to 
tightening of the reimbursement policy. The cases of the 
Czech Republic and Sweden clearly show that the payer 
making decision system was crucial to achieve balanced 
and cost-effective healthcare performance.
Summary
One of the first biosimilar medicines that was ap-
proved in Europe was filgrastim (E. coli recombinant 
G-CSF). This product has been widely used to treat 
and prevent chronic and induced neutropaenia. Be-
fore introduction of the biosimilars, the global market 
of G-CSF was captured by two products: short-acting 
filgrastim (Neupogen®) and long-acting PEG-filgrastim 
(Neulasta®). The situation changed between 2008 and 
2014, when the EMA approved biosimilar versions 
of the filgrastim product. An abbreviated registration 
process allowed limitation of the development costs of 
biosimilars. However, the savings were not equal for all 
sponsors. The development strategy of Sandoz, which 
introduced its product in Europe (2008) and in the US 
(2015) with an optimised set of exercises, turned out to 
be the most cost-effective.
The reduction of the development costs allowed 
price competition and caused the discount not only in 
the biosimilar/reference group, but also in the whole 
product class. On the other hand, the comparison of 
the biosimilar market share and the price reduction 
revealed that there is no correlation between these 
two parameters in European countries. Analysed 
data show that even a low share of biosimilars on the 
market had a significant impact on the price competi-
tion, but a high share did not guarantee a big price 
reduction. 
The price reduction was the factor enhancing the 
uptake of the G-CSF products. However, the uptake 
development varied across European countries. The 
most meaningful growth was observed in Romania, 
Slovakia, Poland, and Slovenia. In Belgium, the Czech 
Republic, Denmark, Ireland, and the Netherlands the 
uptake in the whole product class rose significantly, 
whereas a very low increase or even reduction of the 
uptake in the biosimilar/reference group was noticed. 
On the other hand, in France, Hungary, Italy, and Swe-
den the uptake development in the biosimilar/reference 
group was significantly higher than in the whole product 
class. It seems that such changes in the national markets 
were caused by the mix of the starting price, the start-
ing uptake, the refunding and pricing system of each 
country, and its economic condition.
Figure 6. The change of the overall G-CSF products cost (2013/2006) in Europe. Prepared based on [45]
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Data analysed in this review showed that biosimilar 
introduction changed the market in an expected way. 
The price was reduced and access to the G-CSF products 
for patients was increased. The competition affected not 
only the biosimilar/reference group, but also the whole 
product class. However, these changes were positive also 
for pharmaceutical companies — the overall spendings 
on G-CSF products were higher in 2013 compared to 
2006. The highest growth of spending was noticed in 
Romania (600%) and Poland (213%), the lowest in 
the Czech Republic (3%) and Sweden (6%). These dif-
ferences indicate that in some countries the refunding 
decisions were focused on medicine unit costs rather 
than on the full cost of medicine administration to pa-
tients. It clearly shows that the payer making decision 
system was crucial to achieve balanced and cost-effective 
healthcare performance.
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